🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ever wondered how TNF inh work in #IBD? Curious about the emerging TL1A inhibitors on the horizon? 🌟I've tackled these questions & created a comprehensive summary Full-quality image at ibd-eii.com/ibdcheatsheet More content coming this weekend! Subscribe for free to stay

Out now 🚨 in Gastroenterology is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with Jean-Frederic Colombel Mehandru Lab @MountSinai & Ryan Ungaro MD MS gastrojournal.org/article/S0016-…

🟢 Very happy for the acceptance of our new study for Oral Presentation at #UEGW2024 🗓️ 14/10 Session: Understanding disease primers in IBD 🔬Unconventional T cells in IBD 🤝Collaborative study between Norway 🇳🇴 and Singapore 🇸🇬⁦NTNUnorway⁩ Singapore Immunology Network⁩ Thanks all!

This study 💡 a number of relevant things to remember: ⬆️39% of patients w #IBD had at least another IMID - 45% in #CD and 30% of #UC - Women more likely to have IMIDs ‼️poor knowledge about coexistence of other IMIDs ‼️Highest misconceptions w coexistence of digestive IMID

In a randomized trial in patients with Crohn’s disease in whom anti-TNF therapy had failed, risankizumab was more effective than ustekinumab in achieving clinical and endoscopic remission. Read the full SEQUENCE trial results: nej.md/46dtnFY

SEQUENCE in detail (RIS vs UST in #CD) Summary: RIS non inferior to UST in clinical rem w24 & RIS superior UST in endoscopic rem w48 Some relevant details for me: 1⃣Open label- patients & clinicians knew drug assignment (central reader blinded) this differs from VIVID (MIRI vs

🚨Cellular immunotherapies and immune cell depleting therapies in #IBD: the next magic bullet? #MarkusNeurath Bruce E. Sands Florian Rieder Gut Journal pubmed.ncbi.nlm.nih.gov/39025492/ Fernando Gomollón Y-ECCO Miguel Regueiro Fernando Magro Axel Dignass Paulo G. Kotze Aline Charabaty, MD, FACG, AGAF Peter Higgins Charlie Lees

Risankizumab for Ulcerative Colitis jamanetwork.com/journals/jama/… JAMA Remo Panaccione, MD, FRCPC Jean-Frederic Colombel

Here is my full review of the most impactful papers in IBD so far this year SEQUENCE study compares Risankizumab (RIS) and Ustekinumab in people with Crohn's Disease who have lost response to an anti-TNT medication (IFX or ADA) What is the significance of the picture?

A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogeni… pubmed.ncbi.nlm.nih.gov/39080486/ Progressing towards finding cause and prevention 👍

New Comment—Nuru Noor and colleagues argue the need for more affordable, pragmatic, and investigator-initiated trials in #IBD 📄thelancet.com/journals/langa… #GITwitter Tim Raine Seb

(1) 📢 New American Gastroenterological Association (AGA) Clinical Practice Update on Management of #IBD in Patients With #Malignancy 📢 cghjournal.org/article/S1542-… 🔥🔥An #IBD tweetorial on #Cancer for #GITwitter from Jordan Axelrad, MD, MPH, Jana G Hashash, MD, MSc, #StevenItzkowitz and published in CGH🔥🔥 Follow this🧵

Understanding how drugs work, helps us understand their full potential & adverse effects 🌟In today's back to basics, how do the immunosuppressants used in #IBD & other diseases work? Starting from the intriguing function of methotrexate, efficacious in #CD to maintain

FCP is better for colonic > small bowel (SB) inflammatiin, but how accurate is it in proximal vs. distal SB? Using VCE as gold standard, our Sheba Medical Center brilliant fellow Offir Ukashi reports in Journal of Crohn's and Colitis a dilutional gradient of calpro along the SB ! pubmed.ncbi.nlm.nih.gov/39120437/

🔥Efficacy and safety of #probiotics in #IBD❗️🦠 ✅️Probiotics had a significant effect in inducing clinical #remission in #UC🟢 ❌️Probiotics lacked significant effect in #CD🔴 📕only in UEGJ🥰 👉tinyurl.com/y8f3akpy my_UEG Wiley Clinical Health Y-ECCO #GITwitter

How often during a colonoscopy in a patient w #CD could we have missed lesions that would have led to a change in therapy? I’ve wondered about this many times Virginia Solitano addresses it in her 📄 🔍 22.3% had lesions proximal to the TI 🔍 24.5% SB skip lesions in the ileum 🔍

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

Risankizumab in refractory #CD patients N=53 👫51% B2 & 17% B3 behavior Perianal dis 47% Prior bowel 🔪 79% All had failed at least to 1 antiTNF (>90% to two) + VDZ + UST (and some received off label TOFA) ✅75% persisted at w52 Dont miss out our latest publication

Today is World Suicide Prevention Day Patients with #IBD are at increased risk. There is insufficient data and prevention regarding this situation Let's raise awareness, break the stigma, & remind everyone they’re not alone. Reach out—there’s hope 🙏🏻 #SuicidePrevention

🎭 UEGJ on stage 🎤 With Zsa Zsa Weerts talking on the job as an Editor 📝 Submission & Selection 👨‍⚖️ Role of a peer reviewer 😭 Why is my paper rejected or…. 🤪 Or .. accepted! my_UEG Daniel Keszthelyi MD PhD Ashkan Rezazadeh MD Neesse lab